Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date08 Jan 2024 |
荆门上清丸治疗复发性口腔溃疡(上焦实热证)随机、双盲、安慰剂平行对照、多中心Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of Jingmen Shangqing Pills in the treatment of recurrent oral ulcers (upper-jiao heat syndrome)
以治疗5天后的靶溃疡愈合率为主要疗效指标,通过随机、双盲、安慰剂平行对照、多中心临床试验,确证荆门上清丸治疗复发性口腔溃疡(上焦实热证)的有效性和安全性。
[Translation] The target ulcer healing rate after 5 days of treatment was used as the primary efficacy indicator. A randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted to confirm the effectiveness and safety of Jingmen Shangqing Pills in the treatment of recurrent oral ulcers (upper-jiao heat syndrome).
评价荆门上清丸治疗复发性口腔溃疡的安全性和有效性随机、双盲、安慰剂平行对照、多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the safety and efficacy of Jingmen Shangqing Pills in the treatment of recurrent oral ulcers
以安慰剂为对照,评价荆门上清丸治疗复发性口腔溃疡的有效性及安全性
[Translation] To evaluate the efficacy and safety of Jingmen Shangqing Pills in the treatment of recurrent oral ulcers using placebo as a control
100 Clinical Results associated with Hubei Qijin Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hubei Qijin Pharmaceutical Co., Ltd.
100 Deals associated with Hubei Qijin Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hubei Qijin Pharmaceutical Co., Ltd.